Targeted immune therapies in heart transplantation
心脏移植中的靶向免疫治疗
基本信息
- 批准号:10573846
- 负责人:
- 金额:$ 105.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-01 至 2030-01-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdoptedAlloantigenAllograftingAntibody-drug conjugatesBiological AssayChronicDataDrug Delivery SystemsDrug TargetingGenerationsGoalsHeart DiseasesHeart TransplantationImmuneImmune TargetingImmunotherapeutic agentImmunotherapyInfectionKineticsLifeMalignant NeoplasmsMetabolic syndromeMethodsModelingMusNanotechnologyOrganPatientsPhenotypeResearchT-LymphocyteTechniquesTherapeuticTherapeutic UsesTherapeutic immunosuppressionTimeTissuesToxic effectTransplant RecipientsTransplantationallograft rejectionclinical applicationcollaborative approachdosagedraining lymph nodeexperimental studyheart allograftimaging studyimprovedimproved outcomeinnovationinterestmouse modelmultidisciplinarynanoparticlenovelpost-transplantpreventprogramstargeted deliverytargeted treatmenttraffickingtransplant model
项目摘要
Abstract
Heart transplantation has become the mainstay lifesaving therapeutic strategy for a growing number of patients
with irreversible, end-stage heart disease. However, numerous challenges must be met to improve long term
heart allograft rejection. Although immune therapeutics (ITs) used to prevent rejection have improved over time,
they are still unable to eliminate acute and chronic rejection effectively. The use of more intense and potent IT
regimens, adopted commonly by transplant programs, can reduce the survival of heart transplant patients by
increasing their chances of developing metabolic syndrome, post-transplant malignancy, and serious infection.
Therefore, a significant unmet need exists to develop novel and innovative strategies to increase the efficacy of
ITs and to reduce their toxicity. Although targeted drug delivery using nanotechnology or antibody-drug
conjugates (ADCs) has sparked great interest in the cancer field, its application to transplantation remains to be
developed. Over the past several years, we have made major strides to introduce a wide range of targeted
therapeutics to the heart transplantation research field. In transplantation, presentation of donor allo-antigens to
recipient T cells in the draining lymph nodes (DLN) is fundamental to the generation of alloreactive T cells that
traffic to the allografts and cause rejection. The overall hypothesis of this proposal is that targeted delivery of ITs
to the DLN and allografts not only increases the efficacy of ITs, but it also decreases their toxicity through
reduction of their systemic dosage. In this proposal, we devise a clinically applicable active targeted delivery
method for ITs to LNs and organs to promote allograft acceptance in murine models of heart transplantation. We
also plan to examine the operating mechanisms that result in prolongation of heart allograft survival by our active
targeted delivery platform. These experiments will employ murine heart transplant models, nanoparticle
synthesis, advanced antibody-drug conjugation, comprehensive immune phenotyping assays, and sophisticated
imaging studies to understand the kinetics of T cell trafficking and payloads in the tissue. Supported by our
extensive expertise, as well as established models, techniques, and data, this multidisciplinary collaborative
approach sets forth for the first time a well-balanced, innovative, and clinically applicable targeted delivery
platform. The studies proposed here have the potential to yield results that could be paradigm-shifting in our
approach to immunosuppressive therapy in transplantation.
摘要
心脏移植已成为越来越多的患者的主要救生治疗策略
患有不可逆的晚期心脏病然而,必须应对许多挑战,以改善长期
心脏移植排斥反应虽然用于预防排斥反应的免疫疗法(IT)随着时间的推移而有所改善,
但仍不能有效地消除急性和慢性排斥反应。使用更密集、更有效的IT
移植项目通常采用的方案,可以通过以下方式降低心脏移植患者的存活率:
增加了他们患代谢综合征、移植后恶性肿瘤和严重感染的机会。
因此,存在开发新颖和创新的策略以增加药物治疗的功效的显著未满足的需求。
并降低其毒性。尽管使用纳米技术或抗体-药物靶向给药
尽管ADC在肿瘤领域引起了极大的兴趣,但其在移植中的应用仍有待进一步研究。
开发在过去几年中,我们取得了重大进展,推出了广泛的有针对性的
心脏移植研究领域的新进展。在移植中,将供体同种抗原呈递给
引流淋巴结(DLN)中的受体T细胞是产生同种异体反应性T细胞的基础,
移植物的运输导致排斥反应。本提案的总体假设是,有针对性地提供信息技术
DLN和同种异体移植物不仅增加了IT的疗效,而且还通过以下方式降低了它们的毒性:
减少全身剂量。在这个建议中,我们设计了一个临床上适用的主动靶向给药
在心脏移植的小鼠模型中,用于淋巴结和器官的IT促进同种异体移植物接受的方法。我们
我们还计划研究通过我们的活性药物延长心脏移植物存活的作用机制。
目标交付平台。这些实验将采用鼠心脏移植模型、纳米颗粒、纳米颗粒和纳米颗粒。
合成,先进的抗体-药物缀合,全面的免疫表型分析,以及复杂的
成像研究以了解组织中T细胞运输和有效载荷的动力学。支持我们的
广泛的专业知识,以及建立的模型,技术和数据,这个多学科的合作
该方法首次提出了一种平衡、创新和临床适用的靶向递送
平台这里提出的研究有可能产生的结果,可能是范式转移,在我们的
移植中免疫抑制治疗的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Reza Abdi其他文献
Reza Abdi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Reza Abdi', 18)}}的其他基金
The novel role of beta3 integrin in regulating alloimmunity
β3整合素在调节同种免疫中的新作用
- 批准号:
10573306 - 财政年份:2022
- 资助金额:
$ 105.09万 - 项目类别:
The novel role of beta3 integrin in regulating alloimmunity
β3整合素在调节同种免疫中的新作用
- 批准号:
10467425 - 财政年份:2022
- 资助金额:
$ 105.09万 - 项目类别:
New way in delivering immunomodulatory drugs in T1D
在 T1D 中提供免疫调节药物的新方法
- 批准号:
10576373 - 财政年份:2022
- 资助金额:
$ 105.09万 - 项目类别:
New way in delivering immunomodulatory drugs in T1D
在 T1D 中提供免疫调节药物的新方法
- 批准号:
10457732 - 财政年份:2022
- 资助金额:
$ 105.09万 - 项目类别:
IRI, innate immunity and transplant rejection
IRI、先天免疫和移植排斥
- 批准号:
10576902 - 财政年份:2021
- 资助金额:
$ 105.09万 - 项目类别:
IRI, innate immunity and transplant rejection
IRI、先天免疫和移植排斥
- 批准号:
10371989 - 财政年份:2021
- 资助金额:
$ 105.09万 - 项目类别:
Lymph nodes at the crossroads of allo immunity and regulation
淋巴结处于同种异体免疫和调节的十字路口
- 批准号:
10662304 - 财政年份:2020
- 资助金额:
$ 105.09万 - 项目类别:
HVEM pathway regulating FRC function and transplant tolerance
HVEM 通路调节 FRC 功能和移植耐受
- 批准号:
10662313 - 财政年份:2020
- 资助金额:
$ 105.09万 - 项目类别:
相似海外基金
How novices write code: discovering best practices and how they can be adopted
新手如何编写代码:发现最佳实践以及如何采用它们
- 批准号:
2315783 - 财政年份:2023
- 资助金额:
$ 105.09万 - 项目类别:
Standard Grant
One or Several Mothers: The Adopted Child as Critical and Clinical Subject
一位或多位母亲:收养的孩子作为关键和临床对象
- 批准号:
2719534 - 财政年份:2022
- 资助金额:
$ 105.09万 - 项目类别:
Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2633211 - 财政年份:2020
- 资助金额:
$ 105.09万 - 项目类别:
Studentship
A material investigation of the ceramic shards excavated from the Omuro Ninsei kiln site: Production techniques adopted by Nonomura Ninsei.
对大室仁清窑遗址出土的陶瓷碎片进行材质调查:野野村仁清采用的生产技术。
- 批准号:
20K01113 - 财政年份:2020
- 资助金额:
$ 105.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2436895 - 财政年份:2020
- 资助金额:
$ 105.09万 - 项目类别:
Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2633207 - 财政年份:2020
- 资助金额:
$ 105.09万 - 项目类别:
Studentship
The limits of development: State structural policy, comparing systems adopted in two European mountain regions (1945-1989)
发展的限制:国家结构政策,比较欧洲两个山区采用的制度(1945-1989)
- 批准号:
426559561 - 财政年份:2019
- 资助金额:
$ 105.09万 - 项目类别:
Research Grants
Securing a Sense of Safety for Adopted Children in Middle Childhood
确保被收养儿童的中期安全感
- 批准号:
2236701 - 财政年份:2019
- 资助金额:
$ 105.09万 - 项目类别:
Studentship
A Study on Mutual Funds Adopted for Individual Defined Contribution Pension Plans
个人设定缴存养老金计划采用共同基金的研究
- 批准号:
19K01745 - 财政年份:2019
- 资助金额:
$ 105.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and functional analyses of a bacterial protein translocation domain that has adopted diverse pathogenic effector functions within host cells
对宿主细胞内采用多种致病效应功能的细菌蛋白易位结构域进行结构和功能分析
- 批准号:
415543446 - 财政年份:2019
- 资助金额:
$ 105.09万 - 项目类别:
Research Fellowships